I am bullish on Novo Nordisk due to its 62% global GLP-1 market share and dominant Ozempic sales, supporting long-term leadership. Novo Nordisk's diversified GLP-1 portfolio, including Rybelsus ...

Overview Novo Nordisk NVO has outperformed the market over the past 5 years by 1.33% on an annualized basis producing an average annual return of 15.96%.

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic versions of Novo Nordisk’s lucrative semaglutide drugs for diabetes and ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 countries next year, the Indian drugmaker's CEO, Erez Israeli, said on ...

Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for long-term investors to capitalize now. Learn more on NVO stock here.

Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest portfolios in the sector, with a strong presence in oncology ...

“I want you to know I don’t want Novo Nordisk… and the reason that is because if there’s going to be talk about tariffs on foreign drugs versus Eli Lilly, Novo is going to have an even ...

Eli Lilly LLY, maker of GLP-1s Monjouro and Zepbound, and Novo Nordisk NVO said they're combating unsafe products through lawsuits and consumer education, Reuters reports.

Danish outdoor brand Nordisk has partnered with K2 Korea and China’s BA Capital to establish a strategic joint venture in China, including the opening of the first Nordisk stores in the country. The ...